ABBV logo

AbbVie (ABBV) Depreciation And Amortization

Annual D&A

$8.70 B
+$231.00 M+2.73%

31 December 2023

1-Year Change

+2.73%
ABBV annual depreciation & amortization is up +2.73% year-on-year

3-Year Change

+34.42%
ABBV annual depreciation & amortization is up +34.42% over the past 3 years

All-time High

$8.70 B
ABBV annual depreciation & amortization is currently at an all-time high

Sector Rank

99.91%
ABBV annual depreciation & amortization is higher than 99.91% of companies in Healthcare sector
Annual Total Expenses$40.78 B
ABBV annual total expenses is $40.78 billion
Annual Operating Expenses$20.37 B
ABBV annual total operating expenses is $20.37 billion
Annual Revenue$54.32 B
ABBV annual revenue is $54.32 billion
Annual Net Income$4.86 B
ABBV annual net profit is $4.86 billion

ABBV Depreciation And Amortization Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly D&A

$2.08 B
-$52.00 M-2.44%

30 September 2024

1-Year Change

-6.98%
ABBV quarterly depreciation & amortization is down -6.98% year-on-year

3-Year Change

-2.26%
ABBV quarterly depreciation & amortization is down -2.26% over the past 3 years

All-time High

$2.29 B
ABBV quarterly depreciation & amortization is currently -9.29% below its historical high of $2.29 billion

Sector Rank

99.91%
ABBV quarterly depreciation & amortization is higher than 99.91% of companies in Healthcare sector
Quarterly Total Expenses$10.55 B
ABBV quarterly total expenses is $10.55 billion
Quarterly Operating Expenses$6.33 B
ABBV quarterly total operating expenses is $6.33 billion
Quarterly Revenue$14.46 B
ABBV quarterly revenue is $14.46 billion
Quarterly Net Income$1.56 B
ABBV quarterly net profit is $1.56 billion

ABBV Quarterly D&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM D&A

$8.36 B
-$156.00 M-1.83%

30 September 2024

1-Year Change

-4.77%
ABBV TTM depreciation & amortization is down -4.77% year-on-year

3-Year Change

-2.87%
ABBV TTM depreciation & amortization is down -2.87% over the past 3 years

All-time High

$8.78 B
ABBV TTM depreciation & amortization is currently -4.77% below its historical high of $8.78 billion

Sector Rank

99.91%
ABBV TTM depreciation & amortization is higher than 99.91% of companies in Healthcare sector
Annual Total Expenses$40.78 B
ABBV annual total expenses is $40.78 billion
Annual Operating Expenses$20.37 B
ABBV annual total operating expenses is $20.37 billion
TTM Revenue$55.53 B
ABBV TTM revenue is $55.53 billion
TTM Net Income$5.12 B
ABBV TTM net profit is $5.12 billion

ABBV TTM D&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

ABBV Depreciation And Amortization Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+2.7%-7.0%-4.8%
3 y3 years+34.4%-2.3%-2.9%
5 y5 years+392.8%+313.3%+328.7%

ABBV Depreciation And Amortization High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 yearsat high+34.4%-8.0%+5.0%-4.8%+1.8%
5 y5 yearsat high+392.8%-9.3%+313.3%-4.8%+328.7%
alltimeall timeat high+1147.0%-9.3%+1215.8%-4.8%+2558.4%

AbbVie Depreciation And Amortization History

DateAnnualQuarterlyTTM
Sept 2024
-
$2.08 B(-2.4%)
$8.36 B(-1.8%)
June 2024
-
$2.13 B(+2.7%)
$8.52 B(-1.5%)
Mar 2024
-
$2.07 B(-0.1%)
$8.64 B(-0.6%)
Dec 2023
$8.70 B(+2.7%)
$2.08 B(-7.1%)
$8.70 B(-0.9%)
Sept 2023
-
$2.23 B(-1.1%)
$8.78 B(+0.3%)
June 2023
-
$2.26 B(+6.3%)
$8.75 B(+2.4%)
Mar 2023
-
$2.13 B(-1.4%)
$8.54 B(+0.9%)
Dec 2022
$8.47 B(-0.6%)
$2.16 B(-2.2%)
$8.47 B(+2.1%)
Sept 2022
-
$2.21 B(+7.5%)
$8.29 B(+0.9%)
June 2022
-
$2.05 B(-0.0%)
$8.21 B(-1.8%)
Mar 2022
-
$2.05 B(+3.7%)
$8.36 B(-1.9%)
Dec 2021
$8.52 B(+31.7%)
$1.98 B(-7.0%)
$8.52 B(-1.0%)
Sept 2021
-
$2.13 B(-3.3%)
$8.61 B(-1.9%)
June 2021
-
$2.20 B(-0.7%)
$8.77 B(+7.9%)
Mar 2021
-
$2.21 B(+7.3%)
$8.13 B(+25.6%)
Dec 2020
$6.47 B(+220.8%)
$2.06 B(-9.9%)
$6.47 B(+31.7%)
Sept 2020
-
$2.29 B(+47.4%)
$4.92 B(+57.2%)
June 2020
-
$1.55 B(+178.2%)
$3.13 B(+50.8%)
Mar 2020
-
$559.00 M(+9.8%)
$2.07 B(+2.8%)
Dec 2019
$2.02 B(+14.3%)
$509.00 M(+1.2%)
$2.02 B(+3.4%)
Sept 2019
-
$503.00 M(+0.2%)
$1.95 B(+3.6%)
June 2019
-
$502.00 M(-0.2%)
$1.88 B(+3.2%)
Mar 2019
-
$503.00 M(+13.8%)
$1.82 B(+3.3%)
Dec 2018
$1.76 B(+17.6%)
$442.00 M(+1.6%)
$1.76 B(+4.3%)
Sept 2018
-
$435.00 M(-1.8%)
$1.69 B(+3.4%)
June 2018
-
$443.00 M(-0.4%)
$1.64 B(+4.1%)
Mar 2018
-
$445.00 M(+20.6%)
$1.57 B(+4.7%)
Dec 2017
$1.50 B
$369.00 M(-2.6%)
$1.50 B(+2.8%)
DateAnnualQuarterlyTTM
Sept 2017
-
$379.00 M(0.0%)
$1.46 B(+5.4%)
June 2017
-
$379.00 M(+1.3%)
$1.39 B(+6.9%)
Mar 2017
-
$374.00 M(+14.0%)
$1.29 B(+8.9%)
Dec 2016
$1.19 B(+42.2%)
$328.00 M(+7.9%)
$1.19 B(+6.0%)
Sept 2016
-
$304.00 M(+5.2%)
$1.12 B(+7.4%)
June 2016
-
$289.00 M(+7.8%)
$1.04 B(+10.5%)
Mar 2016
-
$268.00 M(+2.7%)
$946.00 M(+13.2%)
Dec 2015
$836.00 M(+6.4%)
$261.00 M(+15.0%)
$836.00 M(+8.9%)
Sept 2015
-
$227.00 M(+19.5%)
$768.00 M(+4.8%)
June 2015
-
$190.00 M(+20.3%)
$733.00 M(-1.6%)
Mar 2015
-
$158.00 M(-18.1%)
$745.00 M(-5.2%)
Dec 2014
$786.00 M(-12.4%)
$193.00 M(+0.5%)
$786.00 M(-0.9%)
Sept 2014
-
$192.00 M(-5.0%)
$793.00 M(-5.0%)
June 2014
-
$202.00 M(+1.5%)
$835.00 M(-3.9%)
Mar 2014
-
$199.00 M(-0.5%)
$869.00 M(-3.1%)
Dec 2013
$897.00 M(-22.0%)
$200.00 M(-14.5%)
$897.00 M(-10.8%)
Sept 2013
-
$234.00 M(-0.8%)
$1.01 B(+0.7%)
June 2013
-
$236.00 M(+4.0%)
$999.00 M(-5.6%)
Mar 2013
-
$227.00 M(-26.5%)
$1.06 B(-8.0%)
Dec 2012
$1.15 B(-9.6%)
$309.00 M(+36.1%)
$1.15 B(-1.3%)
Sept 2012
-
$227.00 M(-23.1%)
$1.17 B(-7.0%)
June 2012
-
$295.00 M(-7.5%)
$1.25 B(-1.8%)
Mar 2012
-
$319.00 M(-1.8%)
$1.28 B(+0.4%)
Dec 2011
$1.27 B(+7.4%)
$324.68 M(+3.0%)
$1.27 B(+34.3%)
Sept 2011
-
$315.23 M(-0.7%)
$947.32 M(+49.9%)
June 2011
-
$317.61 M(+1.0%)
$632.09 M(+101.0%)
Mar 2011
-
$314.48 M
$314.48 M
Dec 2010
$1.18 B(+69.8%)
-
-
Dec 2009
$697.49 M
-
-

FAQ

  • What is AbbVie annual depreciation & amortization?
  • What is the all time high annual D&A for AbbVie?
  • What is AbbVie annual D&A year-on-year change?
  • What is AbbVie quarterly depreciation & amortization?
  • What is the all time high quarterly D&A for AbbVie?
  • What is AbbVie quarterly D&A year-on-year change?
  • What is AbbVie TTM depreciation & amortization?
  • What is the all time high TTM D&A for AbbVie?
  • What is AbbVie TTM D&A year-on-year change?

What is AbbVie annual depreciation & amortization?

The current annual D&A of ABBV is $8.70 B

What is the all time high annual D&A for AbbVie?

AbbVie all-time high annual depreciation & amortization is $8.70 B

What is AbbVie annual D&A year-on-year change?

Over the past year, ABBV annual depreciation & amortization has changed by +$231.00 M (+2.73%)

What is AbbVie quarterly depreciation & amortization?

The current quarterly D&A of ABBV is $2.08 B

What is the all time high quarterly D&A for AbbVie?

AbbVie all-time high quarterly depreciation & amortization is $2.29 B

What is AbbVie quarterly D&A year-on-year change?

Over the past year, ABBV quarterly depreciation & amortization has changed by -$156.00 M (-6.98%)

What is AbbVie TTM depreciation & amortization?

The current TTM D&A of ABBV is $8.36 B

What is the all time high TTM D&A for AbbVie?

AbbVie all-time high TTM depreciation & amortization is $8.78 B

What is AbbVie TTM D&A year-on-year change?

Over the past year, ABBV TTM depreciation & amortization has changed by -$419.00 M (-4.77%)